Clinical Trial

Evaluation of the Efficacy of Neuromodulation in the Control of Chronic Orofacial Pain

Study acronym: NeuroFace
Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated February 20, 2026 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Chronic orofacial pain significantly affects patients' quality of life, compromising essential functions such as chewing and speech. Although conventional treatments are available, many patients do not achieve adequate and lasting relief. This project investigates the effectiveness of neuromodulation techniques, namely transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS), as innovative therapeutic alternatives for the control of chronic orofacial pain. The study will be conducted in adult patients diagnosed with orofacial pain. Participants will be divided into two groups: one group will receive active neuromodulation (tDCS or TMS) and the other a sham treatment (placebo). Sessions will take place daily over two weeks. Assessments will include pain intensity, pain pressure threshold, masticatory function, and bite strength, in order to observe any functional changes. The group undergoing neuromodulation is expected to show a significant reduction in pain levels and improvements in quality of life compared to the placebo group. This study could support the adoption of neuromodulation as a complementary approach in the treatment of chronic orofacial pain, offering an effective and non-invasive alternative for patients who do not respond to conventional treatments.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-12.
Trial Details
NCT Number NCT07352384
Lead Sponsor Egas Moniz - Cooperativa de Ensino Superior, CRL
Collaborators: University of Sao Paulo, University of Aarhus, Universidade Federal de Alfenas
Conditions Orofacial Pain
Enrollment 50 participants
Start Date 2025-11-01
Primary Completion 2026-05-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-20